HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS British Journal of Psychiatry Psychiatric Bulletin All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in APT Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Timimi, S. Search for Related Content PubMed Articles by Timimi, S.

Child psychiatry and its relationship with the pharmaceutical industry: theoretical and practical issues

Sami Timimi is a consultant child and adolescent psychiatrist who works full time in the National Health Service (Child and Adolescent Mental Health Service, Ash Villa, Willoughby Road, South Rauceby, Sleaford, Lincolnshire NG34 8QA, UK. Email: stimimi{at}talk21.com) and a visiting professor of child and adolescent psychiatry at Lincoln University. He writes from a critical perspective on many topics, including eating disorders, psychotherapy, behavioural disorders and cross-cultural psychiatry.

Abstract

The pharmaceutical industry is primarily responsible to its shareholders and so making profit is its primary motivation. The industry’s marketing techniques affect not only prescribing habits of doctors but also concepts of mental health. This editorial examines the impact this has had on both theory and practice in child and adolescent psychiatry. Undue influence by the pharmaceutical industry contributes to a skewing of the literature towards biological disease models of childhood mental health in order to support the use of the pharmaceutical companies’ products. Using fluoxetine and stimulants as two case examples, the article illustrates how pharmaceutical companies have contributed to widespread acceptance of erroneous beliefs about the safety and efficacy of using psychotropic drugs in children and adolescents. Suggestions are made on how child psychiatrists, both individually and collectively, can incorporate this knowledge into their professional development and practice.

Related articles in APT:

Pharmacotherapy and child psychiatry: is there a way forward?: INVITED COMMENTARY ON... CHILD PSYCHIATRY AND ITS RELATIONSHIP WITH THE PHARMACEUTICAL INDUSTRY

A. James
APT 2008 14: 10-16. [Abstract] [Full Text]